LKT Laboratories, Inc.

BMS-754807

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID B5072
CAS No. 1001350-96-4
Chemical Name (2S)-1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide
Synonym BMS754807; BMS 754807



Formula $C_{23}H_{24}FN_9O$
Formula Wt. 461.51
Melting Point
Purity ≥99%
Solubility

DMSO	92 mg/mL (199.35 mM)
Ethanol	92 mg/mL (199.35 mM)
Water	Insoluble

Store Temp -20°C
Ship Temp Ambient

Pricing and Availability

Bulk quanitites available upon request

Product ID	Size	List Price
B5072	1 mg	$67.80
B5072	5 mg	$127.90
B5072	10 mg	$188.00
B5072	25 mg	$338.00

Description BMS-754807 is an inhibitor of the insulin receptor (InsR) and IGF-1R that exhibits anticancer chemotherapeutic activity. BMS-754807 enhances the efficacy of other co-administered chemotherapeutics, decreasing levels of activated Akt, increasing cleavage of PARP and caspase 3, and inhibiting proliferation in pancreatic ductal adenocarcinoma cells and breast cancer cells in vitro and growth of tumor xenografts in vivo.

References

Awasthi N, Zhang C, Ruan W, et al. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther. 2012 Dec;11(12):2644-53. PMID: 23047891.

Hou X, Huang F, Macedo LF, et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res. 2011 Dec 15;71(24):7597-607. PMID: 22042792.